In addition, resistin was found not to be associated with the metabolic syndrome (by National Cholesterol Education Program’s ATP III and clinical parameters) at baseline and after one year of treatment of RA patients with DMRDs [63]. This evidence concerns the gene RETN and rheumatoid arthritis.